Why the study?
Downstream GPCR G protein and beta-arrestin signaling pathways have conventionally been viewed as mutually exclusive, and novel approaches to modulate GPCR activity may yield unique pharmacological profiles.
The discovery that atazanavir stabilizes a GPCR-G protein-β-arrestin megacomplex reveals a novel mechanism for sustained GPCR signaling, opening new avenues for drug development.
May warrant monitoring for βAR effects in atazanavir-treated patients; extends GPCR pharmacology and drug discovery.
Approximately one-third of clinical drugs mediate their therapeutic effects through G protein-coupled receptors (GPCRs), highlighting their immense therapeutic relevance. Novel approaches to modulate GPCR activity have the potential to yield unique pharmacological profiles. Conventionally, the G protein and β-arrestin signaling pathways downstream of GPCRs have been viewed as mutually exclusive. Using the in-house developed survival pressure selection (SPS) method, a high-throughput platform for GPCR agonist discovery, we identified an allosteric ligand that stabilizes a GPCR-G protein-β-arrestin megacomplex, thereby mediating sustained receptor signaling following internalization. Remarkably, this compound, atazanavir, exhibits pan-receptor activation across multiple family A GPCRs, including GPR119, β1AR, and β2AR, demonstrating the broad applicability of this regulatory mechanism. This discovery uncovers a distinct mechanism of GPCR regulation, opening alternative avenues for the development of therapeutics targeting GPCRs.
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: